MedTrace Logo

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

NCT03978156 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-01-26

No results posted yet for this study

Summary

This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).

Conditions

Interventions

DRUG

Dronabinol 2.5 MG

Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.

DRUG

Microcrystalline cellulose

Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Susanna Curtis, MD · Yale University School of Medicine Oncology Section

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-26
Primary Completion
2021-01-01
Completion
2021-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03978156 on ClinicalTrials.gov